Unity Biotechnology, Inc.UBXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank31
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P31
Within normal range
vs 5Y Ago
-1.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q1 2025 | -8.67% |
| Q4 2024 | 8.90% |
| Q3 2024 | -19.52% |
| Q2 2024 | -9.37% |
| Q1 2024 | 16.81% |
| Q4 2023 | -33.26% |
| Q3 2023 | -24.93% |
| Q2 2023 | 11.89% |
| Q1 2023 | -32.43% |
| Q4 2022 | 5.21% |
| Q3 2022 | 8.67% |
| Q2 2022 | -39.39% |
| Q1 2022 | 30.09% |
| Q4 2021 | 5.48% |
| Q3 2021 | -17.57% |
| Q2 2021 | 26.37% |
| Q1 2021 | -33.41% |
| Q4 2020 | -30.48% |
| Q3 2020 | 16.79% |
| Q2 2020 | -16.31% |
| Q1 2020 | 5.81% |
| Q4 2019 | 2.42% |
| Q3 2019 | -3.74% |
| Q2 2019 | 11.89% |
| Q1 2019 | 1.07% |
| Q4 2018 | 13.78% |
| Q3 2018 | -5.56% |
| Q2 2018 | 16.68% |
| Q1 2018 | 12.37% |
| Q4 2017 | 20.75% |
| Q3 2017 | 4.19% |
| Q2 2017 | 32.18% |
| Q1 2017 | 0.00% |